Sagent Pharmaceuticals (SGNT) shares are up nearly 40% in early trading today after the company agreed to be acquired by Tokyo-based Nichi-Iko Pharmaceutical for ~$736M or $21.75 per share. The all-cash tender offer will commence within 15 business days. The deal will enhance Nichi-Iko's presence in the U.S. market, specifically in injectables and, eventually, biosimilars